Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Neurology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Malignant catatonia and neurological mimics

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Malignant catatonia combines catatonic signs with fever, delirium, autonomic instability and potentially rapid organ failure. Stop non-essential dopamine antagonists, provide critical-care support, treat dehydration and thrombosis risk, give specialist-led benzodiazepine treatment and arrange urgent ECT when response is inadequate or severity is high. Simultaneously investigate encephalitis, non-convulsive status, sepsis and NMS.

Overview

Diagnose catatonia using positive motor and behavioural signs, recognise malignant autonomic deterioration, investigate medical and neurological causes, and use lorazepam and urgent electroconvulsive therapy without worsening the syndrome with dopamine blockade.

Catatonia is not synonymous with unresponsiveness. A patient may be mute and immobile, resist movement without an anatomical reason, maintain an imposed posture, echo speech or alternate stupor with purposeless excitement. Conscious awareness may be retained and later recalled. Examination should describe the signs rather than infer refusal. Repeated command, imitation and tone testing performed respectfully can reveal a reproducible syndrome and offers a baseline for treatment response.

Malignant catatonia lies on a clinical continuum and overlaps with NMS. Both can cause fever, rigidity, altered mental state, autonomic lability, CK elevation and renal injury. Recent dopamine blockade favours NMS, while a catatonic or affective prodrome favours malignant catatonia, but the distinction may remain uncertain. Initial supportive care and benzodiazepines are compatible with both. Antipsychotic exposure should cease, and early ECT discussion is appropriate when catatonia is likely.

Aetiology

01

Mood and psychotic disorders

Severe depression, mania and schizophrenia-spectrum illness can produce catatonia, with malignant autonomic deterioration sometimes following an excited or withdrawn prodrome.

02

Autoimmune and neurological disease

Anti-NMDA-receptor encephalitis, epilepsy, brain injury, neurodegeneration and other neurological disorders can disrupt psychomotor networks and mimic primary psychiatric catatonia.

03

Medicines and withdrawal

Abrupt sedative or dopaminergic change and selected medicines can precipitate catatonic syndromes or closely related hyperthermic rigidity.

04

Infection and metabolic illness

Systemic infection, endocrine disease, electrolyte disturbance and organ failure may cause delirium with catatonic motor signs, particularly in vulnerable people.

Pathophysiology

  1. 1
    Psychomotor network failure

    Dysfunction across frontal, basal-ganglia, thalamic and inhibitory signalling networks impairs initiation, stopping and regulation of movement and behaviour.

  2. 2
    Motor and behavioural entrapment

    The person develops mutism, negativism, posturing, stereotypy or purposeless agitation despite fluctuating awareness and potentially preserved internal experience.

  3. 3
    Autonomic escalation

    Malignant disease activates severe sympathetic and thermogenic responses, causing fever, pressure instability, tachycardia and intense muscle activity.

  4. 4
    Systemic organ injury

    Immobility, dehydration and muscle breakdown then produce aspiration, thrombosis, renal injury, pressure damage and cardiovascular collapse.

Clinical features and red flags

Stuporous catatonia

Marked immobility and mutism coexist with staring, posturing, negativism, waxy flexibility or withdrawal rather than simple sleepiness.

Excited catatonia

Non-goal-directed agitation, impulsivity, stereotyped movement and echophenomena fluctuate with periods of freezing or posturing.

Echophenomena

Automatic repetition of another person's words or movements supplies positive evidence of a psychomotor syndrome rather than deliberate non-engagement.

Malignant evolutionRed flag

New fever, diaphoresis, tachycardia, labile pressure, delirium and rigidity on a catatonic background signals a life-threatening transition.

Autoimmune clue

Rapid psychiatric change followed by seizure, orofacial dyskinesia, reduced speech, autonomic instability or fluctuating consciousness suggests autoimmune encephalitis.

Investigations

  1. 01
    Structured catatonia examinationFirst step
    Why
    Document positive signs and create a treatment-response baseline.
    Interpretation and limitations
    Use a recognised screening scale with direct observation of speech, imitation, tone, posture and automatic behaviour; several concordant signs are required.
  2. 02
    Medicine, substance and withdrawal history
    Why
    Identify antipsychotics, serotonergic agents, benzodiazepine withdrawal and dopaminergic changes.
    Interpretation and limitations
    Exact timing helps distinguish NMS, serotonin toxicity and withdrawal catatonia, but more than one mechanism may coexist.
  3. 03
    Blood count, CRP, CK, renal, liver, thyroid, calcium and glucose
    Why
    Detect infection, rhabdomyolysis, organ injury and metabolic mimics.
    Interpretation and limitations
    CK elevation shows muscle injury but does not separate NMS from malignant catatonia; directed toxicology and autoimmune tests follow the context.
  4. 04
    Electroencephalography
    Why
    Exclude non-convulsive seizures and characterise encephalopathy.
    Interpretation and limitations
    Electrographic seizure activity redirects urgent treatment; diffuse slowing supports brain dysfunction but is not specific for cause.
  5. 05
    MRI brain

Differential diagnosis

01

Neuroleptic malignant syndrome

Recent dopamine blockade or dopaminergic withdrawal with severe rigidity and raised muscle enzymes favours NMS, though substantial overlap with malignant catatonia remains.

02

Serotonin syndrome

Rapid onset after serotonergic exposure with clonus, hyperreflexia and gastrointestinal activation supports serotonin toxicity rather than classic catatonic rigidity.

03

Non-convulsive status epilepticus

Fluctuating responsiveness, subtle twitching or gaze deviation requires urgent EEG because ongoing seizure activity can reproduce mutism and stupor.

04

Locked-in or akinetic mutism

Preserved vertical eye communication suggests locked-in syndrome, while structural frontal or diencephalic injury may cause akinetic mutism without broader catatonic signs.

Additional chapter-specific clues

Locked-in mimic

Quadriplegia with preserved vertical eye movement and awareness after a brainstem event can resemble immobility but lacks the broader catatonic motor signs.

Management

01RecognitionName positive catatonic signsFirst stepA patient is mute, immobile, posturing or unusually agitated.+
  1. 1Assess consciousness, focal neurology, eye movements and cardiorespiratory state, then document mutism, stupor, negativism, posturing, waxy tone and echophenomena.
  2. 2Use a structured catatonia scale and obtain collateral history of mood, psychosis, seizure, infection, medicine changes, substances and autoimmune symptoms.
  3. 3Stop non-essential dopamine antagonists when malignant catatonia or NMS is possible and involve liaison psychiatry and medical or neurological teams early.
02Medical exclusionInvestigate brain and body in parallelCatatonia is new, severe, atypical or accompanied by fever or neurological findings.+
  1. 1Check metabolic, infective, toxic and muscle-injury blood tests and obtain EEG promptly when subtle seizure or unexplained reduced responsiveness is possible.

Complications

01

Hyperthermia and acute kidney injury

Sustained muscle activity causes rhabdomyolysis, hyperkalaemia, acidosis and myoglobin-related kidney injury that may require renal replacement support.

02

Aspiration, thrombosis and pressure injury

Mutism, dysphagia and immobility promote pneumonia, venous thromboembolism, dehydration, malnutrition, contracture and skin breakdown during prolonged immobility.

03

Arrhythmia and circulatory collapse

Autonomic instability and electrolyte disturbance can cause malignant rhythm disturbance, shock and multi-organ failure without rapid treatment.

04

Permanent disability or death

Delayed recognition permits prolonged hypoxia, infection and systemic injury even when the underlying catatonic syndrome is potentially reversible.

Monitoring and follow-up

  • Repeat the same catatonia scale items after lorazepam and across each shift so change is measured rather than described vaguely as more settled.
  • Monitor temperature, heart rate, blood pressure, oxygenation, fluid balance and consciousness frequently during malignant evolution.
  • Trend CK, creatinine, potassium, phosphate, liver tests and coagulation when rigidity, agitation or fever creates rhabdomyolysis and organ risk.
  • Inspect skin, range, oral care, bladder, bowel, nutrition and swallow, preventing pressure injury, contracture and aspiration during immobility.
  • Use ECG and respiratory monitoring during repeated high-dose benzodiazepine or ECT anaesthesia according to local policy.
  • After recovery review memory, mood, psychosis, trauma and the causal neurological or psychiatric illness, documenting future antipsychotic precautions.

Special situations

Immobility may preserve awareness

Some patients later recall conversations during stupor, reinforcing the need for explanation, privacy and respectful care throughout apparent unresponsiveness.

Positive signs make diagnosis

Posturing, waxy flexibility and echophenomena are more useful than merely observing low speech or movement, which has many causes.

Lorazepam is not infallible

A dramatic response is supportive, but severe malignant or chronic catatonia may respond incompletely and still require urgent ECT.

CK does not separate syndromes

Both NMS and malignant catatonia can cause substantial muscle breakdown, so medication timeline and pre-fever behaviour remain important.

ECT is medical rescue

In malignant catatonia it is not an optional last resort after prolonged decline but a potentially life-saving time-critical treatment.

Common pitfalls

  1. 01

    Calling mutism refusal without examining for catatonic signs.

  2. 02

    Assuming catatonia occurs only in schizophrenia.

  3. 03

    Missing autoimmune encephalitis in a first psychiatric-motor syndrome.

  4. 04

    Using CK to distinguish malignant catatonia from NMS absolutely.

  5. 05

    Escalating antipsychotic treatment during fever and rigidity.

  6. 06

    Allowing one failed lorazepam challenge to delay ECT.

  7. 07

    Neglecting thrombosis, pressure, nutrition and aspiration prevention.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
NeurologyOriginal SBA

Positive catatonia sign

A patient is mute and immobile but maintains an examiner-imposed arm posture for several minutes and repeatedly copies the examiner's hand movements. Which interpretation is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Neurology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association for Psychopharmacology catatonia guidelineUK evidence-based consensus on recognition, investigations, benzodiazepines, malignant catatonia and ECT.
  • Royal College of Psychiatrists ECT guidanceUK ECT indications, consent, anaesthesia and treatment principles.
  • Association of British Neurologists guideline resourcesNeurological mimic, encephalitis, EEG and cerebrospinal-fluid assessment context.
  • BNF lorazepam monographUK route, dosing, respiratory cautions and interaction information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Medical assessment must be active. A first catatonic episode, atypical age, seizure, dyskinesia, focal sign or autonomic fluctuation raises encephalitis, especially anti-NMDA-receptor disease. EEG evaluates non-convulsive status; MRI and cerebrospinal fluid assess inflammation or structural disease; toxic and metabolic screening searches reversible causes. Treatment of the underlying disorder proceeds with catatonia care. Exact lorazepam, capacity, anaesthesia and ECT arrangements require liaison psychiatry, neurology and critical-care governance.

Key points

  • Catatonia is a psychomotor syndrome diagnosed by positive signs such as stupor, mutism, negativism, posturing, waxy flexibility, mannerism, stereotypy, agitation, echolalia and echopraxia.
  • It occurs with mood and psychotic disorders but also autoimmune encephalitis, epilepsy, metabolic disease, infection, medicines, substance withdrawal and neurological injury.
  • Malignant catatonia adds hyperthermia, autonomic instability, delirium and laboratory consequences of immobility or muscle activity and can progress to death.
  • A prodrome of excitement, insomnia, psychosis, mutism, negativism or posturing before fever favours malignant catatonia over classic drug-triggered NMS, although overlap is substantial.
  • The Bush-Francis screening items can structure examination and serial response, but scoring never replaces a search for cause or a neurological examination.
  • A lorazepam challenge producing marked temporary improvement supports catatonia, yet non-response does not exclude severe or malignant disease.
  • Avoid starting or escalating antipsychotics while malignant catatonia or NMS remains possible because dopamine blockade can worsen rigidity and autonomic instability.
  • Electroconvulsive therapy is highly effective and time critical for malignant, life-threatening or benzodiazepine-resistant catatonia; referral should begin before prolonged failed drug trials.
  • Prevent aspiration, dehydration, pressure injury, contracture and venous thrombosis, and provide nutrition while preserving dignity and avoiding unnecessary restraint.
  • Anti-NMDA-receptor encephalitis, non-convulsive status, locked-in syndrome, akinetic mutism and severe Parkinsonism are important neurological mimics requiring targeted tests.
Why
Investigate focal signs, first atypical presentation, encephalitis, stroke or structural akinetic mutism.
Interpretation and limitations
Normal imaging does not exclude autoimmune encephalitis, so cerebrospinal fluid and EEG remain important when phenotype is compelling.
  • 06
    Lumbar puncture and autoimmune studies
    Why
    Identify infectious or immune-mediated encephalitis after imaging and safety review.
    Interpretation and limitations
    Send paired cerebrospinal-fluid and serum antibodies through neurology; an isolated non-specific serum result cannot establish autoimmune disease.
  • 07
    Lorazepam challenge
    Why
    Test reversibility of catatonic signs while providing initial treatment.
    Interpretation and limitations
    A rapid objective improvement supports catatonia; absent response in severe disease must not postpone ECT or investigation.
    • 2
    Arrange MRI and cerebrospinal-fluid studies for encephalitis or structural disease, starting empirical antiviral or antimicrobial treatment when clinically indicated.
  • 3Treat dehydration, urinary retention, constipation, aspiration and thrombosis risk while tests proceed, avoiding diagnostic neglect of an immobile patient.
    • 03Benzodiazepine treatmentUse lorazepam with objective reviewCatatonia is clinically likely and cardiorespiratory monitoring is available.+
    1. 1Record baseline scale and function, then give a locally agreed lorazepam challenge with appropriate route and respiratory precautions.
    2. 2Re-examine within the expected time for speech, movement, eye contact and tone, continuing scheduled specialist dosing when response or phenotype supports it.
    3. 3EscalationDo not interpret incomplete response as malingering or automatically escalate antipsychotic treatment; reassess cause and prepare ECT if severe.
    04Malignant syndromeEscalate early to ECT and organ supportEscalationFever, autonomic instability, delirium or organ injury complicates catatonia.+
    1. 1Move to high-dependency or intensive care, actively cool, give fluids, monitor CK, kidney and coagulation and treat aspiration, infection and electrolyte complications.
    2. 2Continue benzodiazepine where safe and initiate urgent ECT referral immediately rather than waiting through multiple low-evidence medicine trials.
    3. 3Coordinate capacity, anaesthesia, court or second-opinion processes and repeated treatments under emergency mental-health and physical-health governance.
    Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
    First-line catatonia treatment and a useful diagnostic probe when objective improvement occurs.

    Lorazepam

    A common diagnostic challenge uses 1 to 2 mg orally, intramuscularly or intravenously with reassessment; ongoing dose and interval follow specialist response and monitoring.

    Monitor airway, respiratory rate, aspiration, falls and paradoxical disinhibition; frailty, lung disease and concurrent sedatives require lower or slower dosing.

    Avoids worsening dopamine-related rigidity, fever and autonomic instability during diagnostic uncertainty.

    Antipsychotic withholding

    Do not administer a further dose while malignant catatonia or NMS is unresolved unless a senior specialist documents an overriding indication and monitoring plan.

    Psychosis still needs humane management with low stimulation and benzodiazepine or ECT pathways; later reintroduction requires recovery, low dose and close observation.

    Reduces immobility-related thrombosis during prolonged stupor or restraint-free bed care.

    Venous-thrombosis prophylaxis

    Use the current hospital pharmacological and mechanical prophylaxis regimen after bleeding, renal, mobility and procedure risks are assessed.

    Review before lumbar puncture and ECT and adjust in renal impairment or bleeding; prophylaxis does not replace hydration and mobilisation when possible.